BIVI BIOVIE INC.

Nasdaq bioviepharma.com


$ 1.94 $ 0.05 (2.63 %)    

Monday, 13-Oct-2025 16:06:29 EDT
QQQ $ 601.69 $ 2.18 (0.36 %)
DIA $ 460.65 $ 2.46 (0.54 %)
SPY $ 662.72 $ 2.37 (0.36 %)
TLT $ 90.59 $ 0.29 (0.32 %)
GLD $ 378.10 $ 1.62 (0.43 %)
$ 1.83
$ 1.90
$ 1.85 x 1
$ 1.95 x 261
$ 1.87 - $ 1.96
$ 1.42 - $ 75.00
223,331
na
13.79M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-15-2025 06-30-2025 10-K
2 05-12-2025 03-31-2025 10-Q
3 02-11-2025 12-31-2024 10-Q
4 11-13-2024 09-30-2024 10-Q
5 09-30-2024 06-30-2024 10-K
6 05-14-2024 03-31-2024 10-Q
7 02-12-2024 12-31-2023 10-Q
8 11-08-2023 09-30-2023 10-Q
9 08-16-2023 06-30-2023 10-K
10 05-12-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-Q
12 11-04-2022 09-30-2022 10-Q
13 09-27-2022 06-30-2022 10-K
14 05-11-2022 03-31-2022 10-Q
15 02-08-2022 12-31-2021 10-Q
16 11-10-2021 09-30-2021 10-Q
17 08-30-2021 06-30-2021 10-K
18 05-10-2021 03-31-2021 10-Q
19 01-29-2021 12-31-2020 10-Q
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-K
22 05-13-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-Q
24 11-19-2019 09-30-2019 10-Q
25 09-27-2019 06-30-2019 10-K
26 05-10-2019 03-31-2019 10-Q
27 02-12-2019 12-31-2018 10-Q
28 11-14-2018 09-30-2018 10-Q
29 10-05-2018 06-30-2018 10-K
30 05-14-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 11-08-2017 09-30-2017 10-Q
33 08-24-2017 06-30-2017 10-K
34 05-09-2017 03-31-2017 10-Q
35 02-07-2017 12-31-2016 10-Q
36 11-16-2016 09-30-2016 10-Q
37 09-28-2016 06-30-2016 10-K
38 05-23-2016 03-31-2016 10-Q
39 02-16-2016 12-31-2015 10-Q
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-biovie-prices-12m-public-offering-of-6m-units-consisting-of-common-stock-and-warrants-at-200-per-unit

Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the...

 biovie-to-implement-1-for-10-reverse-stock-split-effective-july-7-2025

- SEC Filing

 biovie-to-present-patient-centric-design-and-accessibility-of-ongoing-sunrise-pd-phase-2-clinical-trial-at-advanced-therapeutics-in-movement--related-disorders-congress

BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug ther...

 biovie-enrolls-first-patient-in-phase-2-address-lc-clinical-trial-evaluating-bezisterim-for-treatment-of-neurological-symptoms-associated-with-long-covid-expects-topline-data-to-be-available-in-h1-2026

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with m...

 biovie-announces-it-will-present-rationale-and-design-of-phase-2-sunrise-pd-clinical-trial-at-30th-world-congress-on-parkinsons-disease-and-related-disorders-may-7-10-2025-in-new-york-city

BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug ther...

 biovie-opens-patient-enrollment-for-phase-2-sunrise-pd-clinical-trial-evaluating-the-safety-and-efficacy-of-bezisterim-on-motor-and-non-motor-symptoms-in-patients-with-parkinsons-disease-who-havent-been-treated-with-carbidopalevodopa-topline-data-expected-in-late-2025-or-early-2026

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson&...

 biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long-covid-at-the-demystifying-long-covid-international-conference

BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug the...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION